ABSTRACT
Delivery to peripheral lymphatics can be achieved following interstitial administration of nano-sized delivery systems (nanoparticles, liposomes, dendrimers etc) or molecules that hitchhike on endogenous nano-sized carriers (such as albumin). The published work concerning the hitchhiking approach has mostly focussed on the lymphatic uptake of vaccines conjugated directly to albumin binding moieties (ABMs such as lipids, Evans blue dye derivatives or peptides) and their subsequent trafficking into draining lymph nodes. The mechanisms underpinning access and transport of these constructs into lymph fluid, including potential interaction with other endogenous nanocarriers such as lipoproteins, have largely been ignored. Recently, we described a series of brush polyethylene glycol (PEG) polymers containing end terminal short-chain or medium-chain hydrocarbon tails (1C2 or 1C12, respectively), cholesterol moiety (Cho), or medium-chain or long-chain diacylglycerols (2C12 or 2C18, respectively). We evaluated the association of these materials with albumin and lipoprotein in rat plasma, and their intravenous (IV) and subcutaneous (SC) pharmacokinetic profiles. Here we fully detail the association of this suite of polymers with albumin and lipoproteins in rat lymph, which is expected to facilitate lymph transport of the materials from the SC injection site. Additionally, we characterise the thoracic lymph uptake, tissue and lymph node biodistribution of the lipidated brush PEG polymers following SC administration to thoracic lymph cannulated rats. All polymers had moderate lymphatic uptake in rats following SC dosing with the lymph uptake higher for 1C2-PEG, 2C12-PEG and 2C18-PEG (5.8%, 5.9% and 6.7% dose in lymph, respectively) compared with 1C12-PEG and Cho-PEG (both 1.5% dose in lymph). The enhanced lymph uptake of 1C2-PEG, 2C12-PEG and 2C18-PEG appeared related to their association profile with different lipoproteins. The five polymers displayed different biodistribution patterns in major organs and tissues in mice. All polymers reached immune cells deep within the inguinal lymph nodes of mice following SC dosing. The ability to access these immune cells suggests the potential of the polymers as platforms for the delivery of vaccines and immunotherapies. Future studies will focus on evaluating the lymphatic targeting and therapeutic potential of drug or vaccine-loaded polymers in pre-clinical disease models.
Subject(s)
Polyethylene Glycols , Animals , Polyethylene Glycols/chemistry , Polyethylene Glycols/pharmacokinetics , Tissue Distribution , Male , Rats, Sprague-Dawley , Lipids/chemistry , Lymph Nodes/metabolism , Lymph/metabolism , Mice , Rats , Albumins/administration & dosage , Albumins/pharmacokinetics , Lipoproteins/pharmacokinetics , Lipoproteins/administration & dosage , FemaleABSTRACT
BACKGROUND: In the nation-wide double-blind cluster-randomised Finnish Invasive Pneumococcal disease trial (FinIP, ClinicalTrials.gov NCT00861380, NCT00839254), we assessed the indirect impact of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against five pneumococcal disease syndromes. METHODS: Children 6 weeks to 18 months received PHiD-CV10 in 48 clusters or hepatitis B/A-vaccine as control in 24 clusters according to infant 3+1/2+1 or catch-up schedules in years 2009-2011. Outcome data were collected from national health registers and included laboratory-confirmed and clinically suspected invasive pneumococcal disease (IPD), hospital-diagnosed pneumonia, tympanostomy tube placements (TTP) and outpatient antimicrobial prescriptions. Incidence rates in the unvaccinated population in years 2010-2015 were compared between PHiD-CV10 and control clusters in age groups <5 and ≥5 years (5-7 years for TTP and outpatient antimicrobial prescriptions), and in infants <3 months. PHiD-CV10 was introduced into the Finnish National Vaccination Programme (PCV-NVP) for 3-month-old infants without catch-up in 9/2010. RESULTS: From 2/2009 to 10/2010, 45398 children were enrolled. Vaccination coverage varied from 29 to 61% in PHiD-CV10 clusters. We detected no clear differences in the incidence rates between the unvaccinated cohorts of the treatment arms, except in single years. For example, the rates of vaccine-type IPD, non-laboratory-confirmed IPD and empyema were lower in PHiD-CV10 clusters compared to control clusters in 2012, 2015 and 2011, respectively, in the age-group ≥5 years. CONCLUSIONS: This is the first report from a clinical trial evaluating the indirect impact of a PCV against clinical outcomes in an unvaccinated population. We did not observe consistent indirect effects in the PHiD-CV10 clusters compared to the control clusters. We consider that the sub-optimal trial vaccination coverage did not allow the development of detectable indirect effects and that the supervening PCV-NVP significantly diminished the differences in PHiD-CV10 vaccination coverage between the treatment arms.
Subject(s)
Bacterial Proteins/administration & dosage , Carrier Proteins/administration & dosage , Haemophilus Infections/prevention & control , Haemophilus Vaccines/administration & dosage , Haemophilus influenzae/immunology , Immunoglobulin D/administration & dosage , Lipoproteins/administration & dosage , Pneumococcal Vaccines/administration & dosage , Pneumonia, Bacterial/prevention & control , Bacterial Proteins/adverse effects , Bacterial Proteins/immunology , Carrier Proteins/adverse effects , Carrier Proteins/immunology , Child , Child, Preschool , Double-Blind Method , Female , Haemophilus Infections/immunology , Haemophilus Vaccines/adverse effects , Haemophilus Vaccines/immunology , Humans , Immunoglobulin D/adverse effects , Immunoglobulin D/immunology , Infant , Lipoproteins/adverse effects , Lipoproteins/immunology , Male , Pneumococcal Vaccines/adverse effects , Pneumococcal Vaccines/immunology , Pneumonia, Bacterial/immunology , Vaccines, Conjugate/administration & dosage , Vaccines, Conjugate/adverse effects , Vaccines, Conjugate/immunologyABSTRACT
Lung-localized CD4 T cells play a critical role in the control of influenza virus infection and can provide broadly protective immunity. However, current influenza vaccination strategies primarily target influenza hemagglutinin (HA) and are administered peripherally to induce neutralizing antibodies. We have used an intranasal vaccination strategy targeting the highly conserved influenza nucleoprotein (NP) to elicit broadly protective lung-localized CD4 T cell responses. The vaccine platform consists of a self-assembling nanolipoprotein particle (NLP) linked to NP with an adjuvant. We have evaluated the functionality, in vivo localization, and persistence of the T cells elicited. Our study revealed that intranasal vaccination elicits a polyfunctional subset of lung-localized CD4 T cells that persist long term. A subset of these lung CD4 T cells localize to the airway, where they can act as early responders following encounter with cognate antigen. Polyfunctional CD4 T cells isolated from airway and lung tissue produce significantly more effector cytokines IFN-γ and TNF-α, as well as cytotoxic functionality. When adoptively transferred to naive recipients, CD4 T cells from NLP:NP-immunized lung were sufficient to mediate 100% survival from lethal challenge with H1N1 influenza virus. IMPORTANCE Exploiting new, more efficacious strategies to potentiate influenza virus-specific immune responses is important, particularly for at-risk populations. We have demonstrated the promise of direct intranasal protein vaccination to establish long-lived immunity in the lung with CD4 T cells that possess features and positioning in the lung that are associated with both immediate and long-term immunity, as well as demonstrating direct protective potential.
Subject(s)
Antigens, Viral/immunology , CD4-Positive T-Lymphocytes/immunology , Influenza Vaccines/immunology , Lung/immunology , Orthomyxoviridae Infections/prevention & control , Vaccination/methods , Adjuvants, Immunologic/administration & dosage , Adjuvants, Immunologic/chemistry , Administration, Intranasal , Adoptive Transfer , Animals , Antigens, Viral/administration & dosage , Antigens, Viral/chemistry , CD4-Positive T-Lymphocytes/transplantation , Immunity, Mucosal , Immunization, Secondary , Immunologic Memory , Influenza A Virus, H1N1 Subtype/immunology , Influenza Vaccines/administration & dosage , Influenza Vaccines/chemistry , Lipoproteins/administration & dosage , Lipoproteins/chemistry , Lipoproteins/immunology , Lung/blood supply , Mice , Nanoparticles/administration & dosage , Nanoparticles/chemistry , Nucleocapsid Proteins/chemistry , Nucleocapsid Proteins/immunology , Orthomyxoviridae Infections/immunology , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/transplantationABSTRACT
BACKGROUND: It remains unclear whether red meat consumption is causatively associated with cardiovascular disease (CVD) risk, and few randomized controlled studies have examined the effect of incorporating lean beef into a healthy dietary pattern. OBJECTIVES: To evaluate the effects of a Mediterranean (MED) diet (carbohydrate 42%, protein 17%, fat 41%, SFAs 8%, MUFAs 26%, PUFAs 8%) with 14 (MED0.5; 0.5 oz), 71 (MED2.5; 2.5 oz), and 156 (MED5.5; 5.5 oz) g/d/2000 kcal lean beef compared with an average American diet (AAD; carbohydrate 52%, protein 15%, fat 33%, SFAs 12%, MUFAs 13%, PUFAs 8%) on lipid and lipoprotein concentrations, particle number, and size. METHODS: This was a multicenter, 4-period controlled feeding, randomized crossover study. Fifty-nine generally healthy males and females (BMI 20-38 kg/m2; age 30-65 y) consumed each diet for 4 wk with a ≥1-wk washout between the diets. Fasting blood samples were collected at baseline and at the end of each 4-wk period. Lipid subfractions were measured by NMR. RESULTS: Compared with the AAD, all 3 MED diets decreased LDL cholesterol (MED0.5: -10.3 mg/dL; 95% CI: -5.4, -15.7 mg/dL; MED2.5: -9.1 mg/dL; 95% CI: -3.9, -14.3 mg/dL; MED5.5: -6.9 mg/dL; 95% CI: -1.7, -12.1 mg/dL; P < 0.0001). All MED diets elicited similar reductions in total LDL particle number compared with baseline (P < 0.005); however, significant decreases only occurred with MED0.5 (-91.2 nmol/L; 95% CI: -31.4, -151.0 nmol/L) and MED2.5 (-85.3 nmol/L; 95% CI: -25.4, -145.2 nmol/L) compared with AAD (P < 0.003). Compared with the AAD, non-HDL cholesterol (P < 0.01) and apoB (P < 0.01) were lower following the 3 MED diets; there were no differences between the MED diets. All diets reduced HDL-cholesterol and HDL particle number from baseline (P < 0.01). CONCLUSIONS: Lipid and lipoprotein lowering was not attenuated with the inclusion of lean beef in amounts ≤71 g (2.5 oz)/d as part of a healthy low-saturated-fat Mediterranean-style diet.This study is registered at clinicaltrials.gov as NCT02723617.
Subject(s)
Diet, Mediterranean , Lipids/administration & dosage , Lipoproteins/administration & dosage , Red Meat , Animals , Cattle , Cholesterol/blood , Cross-Over Studies , Female , Humans , Male , Middle AgedABSTRACT
BACKGROUND: Bacillus ancthracis causes cutaneous, pulmonary, or gastrointestinal forms of anthrax. B. anthracis is a pathogenic bacterium that is potentially to be used in bioterrorism because it can be produced in the form of spores. Currently, protective antigen (PA)-based vaccines are being used for the prevention of anthrax, but it is necessary to develop more safe and effective vaccines due to their prolonged immunization schedules and adverse reactions. METHODS: We selected the lipoprotein GBAA0190, a potent inducer of host immune response, present in anthrax spores as a novel potential vaccine candidate. Then, we evaluated its immune-stimulating activity in the bone marrow-derived macrophages (BMDMs) using enzyme-linked immunosorbent assay (ELISA) and Western blot analysis. Protective efficacy of GBAA0190 was evaluated in the guinea pig (GP) model. RESULTS: The recombinant GBAA0190 (r0190) protein induced the expression of various inflammatory cytokines including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and macrophage inflammatory protein-1α (MIP-1α) in the BMDMs. These immune responses were mediated through toll-like receptor 1/2 via activation of mitogen-activated protein (MAP) kinase and Nuclear factor-κB (NF-κB) pathways. We demonstrated that not only immunization of r0190 alone, but also combined immunization with r0190 and recombinant PA showed significant protective efficacy against B. anthracis spore challenges in the GP model. CONCLUSIONS: Our results suggest that r0190 may be a potential target for anthrax vaccine.
Subject(s)
Anthrax Vaccines/immunology , Anthrax/prevention & control , Bacillus anthracis/immunology , Lipoproteins/immunology , Animals , Anthrax Vaccines/administration & dosage , Anthrax Vaccines/genetics , Cytokines/metabolism , Guinea Pigs , Immunization , Lipoproteins/administration & dosage , Lipoproteins/genetics , Macrophages/immunology , Macrophages/metabolism , Mice , Mitogen-Activated Protein Kinases/metabolism , NF-kappa B/metabolism , Recombinant Proteins/administration & dosage , Recombinant Proteins/genetics , Recombinant Proteins/immunology , Signal Transduction , Spores, Bacterial/immunology , Toll-Like Receptors/metabolismABSTRACT
BURKHOLDERIA MALLEI: is a highly pathogenic bacterium that causes the fatal zoonosis glanders. The organism specifies multiple membrane proteins, which represent prime targets for the development of countermeasures given their location at the host-pathogen interface. We investigated one of these proteins, Pal, and discovered that it is involved in the ability of B. mallei to resist complement-mediated killing and replicate inside host cells in vitro, is expressed in vivo and induces antibodies during the course of infection, and contributes to virulence in a mouse model of aerosol infection. A mutant in the pal gene of the B. mallei wild-type strain ATCC 23344 was found to be especially attenuated, as BALB/c mice challenged with the equivalent of 5,350 LD50 completely cleared infection. Based on these findings, we tested the hypothesis that a vaccine containing the Pal protein elicits protective immunity against aerosol challenge. To achieve this, the pal gene was cloned in the vaccine vector Parainfluenza Virus 5 (PIV5) and mice immunized with the virus were infected with a lethal dose of B. mallei. These experiments revealed that a single dose of PIV5 expressing Pal provided 80% survival over a period of 40 days post-challenge. In contrast, only 10% of mice vaccinated with a PIV5 control virus construct survived infection. Taken together, our data establish that the Peptidoglycan-associated lipoprotein Pal is a critical virulence determinant of B. mallei and effective target for developing a glanders vaccine.
Subject(s)
Bacterial Vaccines/immunology , Burkholderia mallei/chemistry , Burkholderia mallei/pathogenicity , Lipoproteins/immunology , Melioidosis/prevention & control , Peptidoglycan/chemistry , Aerosols , Animals , Bacterial Vaccines/administration & dosage , Burkholderia mallei/immunology , Cell Line , Female , Genetic Vectors , Immunization , Lipoproteins/administration & dosage , Macrophages/microbiology , Melioidosis/immunology , Mice , Mice, Inbred BALB C , Parainfluenza Virus 5/genetics , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/immunology , VirulenceABSTRACT
Lipoproteins (LPs) are circulating heterogeneous nanoparticles produced by the liver and intestines. LPs play a major role in the transport of dietary and endogenous lipids to target cells through cell membrane receptors or cell surface-bound lipoprotein lipase. The stability, biocompatibility, and selective transport of LPs make them promising delivery vehicles for various therapeutic and imaging agents. This review discusses isolation, manufacturing, and drug loading techniques used for LP-based drug delivery, as well as recent applications for diagnosis and treatment of cancer, atherosclerosis, and other life-threatening diseases.
Subject(s)
Drug Delivery Systems , Lipoproteins/administration & dosage , Animals , Humans , Lipoproteins/biosynthesis , Lipoproteins/chemical synthesis , Lipoproteins/isolation & purificationABSTRACT
Hemophilia A (HA) and B (HB) are X-linked bleeding disorders caused by mutations in the F8 or F9 gene that result in the absence, or reduced activity, of the corresponding clotting factor. The severity of bleeding and related complications is proportional to the amount of residual circulating functional factor. The development of a safe and effective hemophilia treatment lasted several decades and has been mainly based on clotting factor replacement. Advances in the engineering and manufacturing of clotting concentrates have led to the widespread availability of extended half-life products that reduced the number of intravenous infusions needed to achieve adequate trough levels. The recent development of new nonfactor replacement treatments and biotechnology techniques has offered therapeutic alternatives for hemophilia patients with and without inhibitors. These are characterized by an easier route of administration, low immunogenicity, and, regarding gene therapy and cell-based treatments, potential long-term protection from bleeding after a single treatment course. In this review, we analyze recent progresses in the management of hemophilia and discuss opportunities and challenges.
Subject(s)
Blood Coagulation Factors/therapeutic use , Hemophilia A/therapy , Hemophilia B/therapy , Hemorrhage/prevention & control , Acetylgalactosamine/administration & dosage , Acetylgalactosamine/pharmacology , Acetylgalactosamine/therapeutic use , Antibodies, Bispecific/administration & dosage , Antibodies, Bispecific/pharmacology , Antibodies, Bispecific/therapeutic use , Antibodies, Monoclonal, Humanized/administration & dosage , Antibodies, Monoclonal, Humanized/pharmacology , Antibodies, Monoclonal, Humanized/therapeutic use , Blood Coagulation Factors/administration & dosage , Clinical Trials as Topic , Coagulants/administration & dosage , Coagulants/therapeutic use , Factor IX/administration & dosage , Factor IX/genetics , Factor IX/therapeutic use , Factor VIII/administration & dosage , Factor VIII/genetics , Factor VIII/therapeutic use , Genetic Therapy/methods , Hemophilia A/complications , Hemophilia A/genetics , Hemophilia B/complications , Hemophilia B/genetics , Hemorrhage/etiology , Hemorrhage/mortality , History, 20th Century , Humans , Infusions, Intravenous , Injections, Subcutaneous , Laboratories/statistics & numerical data , Life Expectancy/history , Life Expectancy/trends , Lipoproteins/administration & dosage , Lipoproteins/pharmacology , Lipoproteins/therapeutic use , RNA, Small Interfering/administration & dosage , RNA, Small Interfering/pharmacology , RNA, Small Interfering/therapeutic use , Severity of Illness IndexABSTRACT
Lipoproteins are naturally occurring nanoparticles and their main physiological function is the promotion of lipid metabolism. They can be prepared in vitro for use as drug carriers, and these reconstituted lipoproteins show similar biological activity to their natural counterparts. Some lipoproteins can cross the blood-retinal barrier and are involved in intraocular lipid metabolism. Drug-loaded lipoproteins can be delivered to the retina for the treatment of posterior eye diseases. In this review, we have discussed the therapeutic applications of lipoproteins for eye diseases and introduced the emerging animal models used for the evaluation of their therapeutic effects.
Subject(s)
Drug Delivery Systems , Eye Diseases/drug therapy , Lipoproteins/administration & dosage , Nanoparticles/administration & dosage , Animals , Eye/metabolism , Eye Diseases/metabolism , Humans , Lipid Metabolism , Lipoproteins/chemistry , Nanoparticles/chemistryABSTRACT
Brucellosis is a zoonotic disease threatening the public health and hindering the trade of animals and their products, which has a negative impact on the economic development of a country. Vaccination is the most effective way to control brucellosis. The recombinant vector vaccines are promising candidates for immunization in humans and animals. In this study, the gene encoding OMP19 antigen was primarily amplified and cloned into an expression vector called pT1NX, and then transformed to L. casei cell via electroporation technique. The expression was confirmed using specific antibody against the recombinant protein via immunological screening tests such as western blot and immunofluorescence assay. Finally, recombinant L. casei was orally fed to mice and the results were further recorded, indicating that the mice group which received OMP19 through L. casei based vaccine represented a very good general and mucosal immune responses protective against challenges with virulent B. abortus 544 strain compared with negative control recipient groups. Therefore, the vaccine produced in this research plan can be a very good candidate for protection against brucellosis.
Subject(s)
Antibodies, Bacterial/blood , Antigens, Bacterial/immunology , Bacterial Outer Membrane Proteins/immunology , Brucella Vaccine/immunology , Brucellosis/prevention & control , Lacticaseibacillus casei/genetics , Lipoproteins/immunology , Administration, Oral , Animals , Antigens, Bacterial/administration & dosage , Bacterial Outer Membrane Proteins/administration & dosage , Brucella Vaccine/administration & dosage , Brucella abortus , Brucellosis/immunology , Cytokines/immunology , Female , Humans , Immunity, Humoral , Immunity, Mucosal , Lipoproteins/administration & dosage , Mice , Mice, Inbred BALB C , Probiotics/administration & dosage , Vaccination/methods , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/immunologyABSTRACT
The development of vaccines for prevention of diseases caused by pathogenic species can encounter major obstacles if high sequence diversity is observed between individual strains. Therefore, development might be restricted either to conserved antigens, which are often rare, or to multivalent vaccines, which renders the production more costly and cumbersome. In light of this complexity, we applied a structure-based surface shaping approach for the development of a Lyme borreliosis (LB) vaccine suitable for the United States and Europe. The surface of the C-terminal fragment of outer surface protein A (OspA) was divided into distinct regions, based primarily on binding sites of monoclonal antibodies (MAbs). In order to target the six clinically most relevant OspA serotypes (ST) in a single protein, exposed amino acids of the individual regions were exchanged to corresponding amino acids of a chosen OspA serotype. Six chimeric proteins were constructed, and, based on their immunogenicity, four of these chimeras were tested in mouse challenge models. Significant protection could be demonstrated for all four proteins following challenge with infected ticks (OspA ST1, OspA ST2, and OspA ST4) or with in vitro-grown spirochetes (OspA ST1 and OspA ST5). Two of the chimeric proteins were linked to form a fusion protein, which provided significant protection against in vitro-grown spirochetes (OspA ST1) and infected ticks (OspA ST2). This article presents the proof-of-concept study for a multivalent OspA vaccine targeting a wide range of pathogenic LB Borrelia species with a single recombinant antigen for prevention of Lyme borreliosis.
Subject(s)
Antigens, Surface/immunology , Bacterial Outer Membrane Proteins/immunology , Bacterial Vaccines/immunology , Borrelia/immunology , Lipoproteins/immunology , Lyme Disease/prevention & control , Recombinant Proteins/immunology , Animals , Antigens, Surface/administration & dosage , Antigens, Surface/genetics , Bacterial Outer Membrane Proteins/administration & dosage , Bacterial Outer Membrane Proteins/genetics , Bacterial Vaccines/administration & dosage , Bacterial Vaccines/genetics , Borrelia/genetics , Disease Models, Animal , Lipoproteins/administration & dosage , Lipoproteins/genetics , Mice , Protein Engineering , Recombinant Proteins/genetics , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunologyABSTRACT
BACKGROUND/PURPOSE: HtsA (Streptococcus heme transporter A) is the lipoprotein component of the streptococcal heme ABC transporter (HtsABC). The aim of this study is to investigate whether the HtsA protein has immunoprotective effect against group A Streptococcus (GAS) infection in mice. METHODS: The HtsA protein was purified by sequential chromatography on Ni-sepharose, DEAE-sepharose and Phenyl-sepharose, CD-1 mice were actively immunized with ALUM (control) or HtsA/ALUM, and passively immunized with control or anti-HtsA serum. Mice were challenged with GAS after immunization, and the survival rate, skin lesion size and systemic GAS dissemination were determined. RESULTS: The HtsA gene was cloned, and the recombinant protein HtsA was successfully purified. HtsA has a strong antigenicity, and active immunization with the HtsA protein significantly protected mice against lethal subcutaneous GAS infection, inhibited invasion of the skin by GAS, and reduced GAS systemic dissemination in blood and organs. In addition, passive immunization with anti-HtsA serum also significantly protected mice against subcutaneous GAS infection, and inhibited invasion of the skin by GAS. CONCLUSION: The results showed that both active and passive immunization with the HtsA protein protected mice against subcutaneous GAS infection, suggesting that HtsA may be a candidate of GAS vaccine to protect against GAS infection.
Subject(s)
Bacterial Proteins/immunology , Heme-Binding Proteins/immunology , Immunization, Passive , Lipoproteins/immunology , Streptococcal Infections/prevention & control , Vaccination , Animals , Bacterial Proteins/administration & dosage , Female , Heme-Binding Proteins/administration & dosage , Immunoglobulin G/blood , Immunoglobulin G/immunology , Lipoproteins/administration & dosage , Mice , Recombinant Proteins/administration & dosage , Recombinant Proteins/immunology , Streptococcal Infections/immunologyABSTRACT
Lipoproteins are a family of naturally occurring macromolecular complexes consisting amphiphilic apoproteins, phospholipids, and neutral lipids. The physiological role of mammalian plasma lipoproteins is to transport their apolar cargo (primarily cholesterol and triglyceride) to their respective destinations through a highly organized ligand-receptor recognition system. Current day synthetic nanoparticle delivery systems attempt to accomplish this task; however, many only manage to achieve limited results. In recent years, many research labs have employed the use of lipoprotein or lipoprotein-like carriers to transport imaging agents or drugs to tumors. The purpose of this review is to highlight the pharmacologic, clinical, and molecular evidence for utilizing lipoprotein-based formulations and discuss their scientific rationale. To accomplish this task, evidence of dynamic drug interactions with circulating plasma lipoproteins are presented. This is followed by epidemiologic and molecular data describing the association between cholesterol and cancer.
Subject(s)
Lipoproteins/administration & dosage , Neoplasms/drug therapy , Animals , Cholesterol/metabolism , Drug Delivery Systems/methods , Drug Interactions/physiology , Humans , Nanoparticles/administration & dosage , Neoplasms/metabolismABSTRACT
Vaccinations with the 10-valent pneumococcal conjugated vaccine (PHiD-CV) started in Iceland in 2011. Protein D (PD) from H. influenzae, which is coded for by the hpd gene, is used as a conjugate in the vaccine and may provide protection against PD-positive H. influenzae We aimed to evaluate the effect of PHiD-CV vaccination on H. influenzae in children, both in carriage and in acute otitis media (AOM). H. influenzae was isolated from nasopharyngeal swabs collected from healthy children attending 15 day care centers in 2009 and from 2012 to 2017 and from middle ear (ME) samples from children with AOM collected from 2012 to 2017. All isolates were identified using PCR for the hpd and fucK genes. Of the 3,600 samples collected from healthy children, 2,465 were culture positive for H. influenzae (68.5% carriage rate); of these, 151 (6.1%) contained hpd-negative isolates. Of the 2,847 ME samples collected, 889 (31.2%) were culture positive for H. influenzae; of these, 71 (8.0%) were hpd negative. Despite the same practice throughout the study, the annual number of ME samples reduced from 660 in 2012 to 330 in 2017. The proportions of hpd-negative isolates in unvaccinated versus vaccinated children were 5.6% and 7.0%, respectively, in healthy carriers, and 5.4% and 7.8%, respectively, in ME samples. The proportion of hpd-negative isolates increased with time in ME samples but not in healthy carriers. The number of ME samples from children with AOM decreased. The PHiD-CV had no effect on the proportion of the hpd gene in H. influenzae from carriage, but there was an increase in hpd-negative H. influenzae in otitis media. The proportions of hpd-negative isolates remained similar in vaccinated and unvaccinated children.
Subject(s)
Bacterial Proteins/administration & dosage , Carrier Proteins/administration & dosage , Carrier State/microbiology , Haemophilus Infections/microbiology , Haemophilus influenzae/isolation & purification , Immunoglobulin D/administration & dosage , Lipoproteins/administration & dosage , Otitis Media/microbiology , Pneumococcal Vaccines/administration & dosage , Bacterial Proteins/genetics , Carrier Proteins/genetics , Carrier State/prevention & control , Child , Child, Preschool , Ear, Middle/microbiology , Haemophilus Infections/prevention & control , Haemophilus influenzae/genetics , Humans , Iceland/epidemiology , Immunoglobulin D/genetics , Infant , Lipoproteins/genetics , Nasopharynx/microbiology , Otitis Media/prevention & control , Vaccines, Conjugate/administration & dosageABSTRACT
The study of capture and processing of antigens (Ags) by intestinal epithelial cells is very important for development of new oral administration systems. Efficient oral Ag delivery systems must resist enzymatic degradation by gastric and intestinal proteases and deliver the Ag across biological barriers. The recombinant unlipidated outer membrane protein from Brucella spp. (U-Omp19) is a protease inhibitor with immunostimulatory properties used as adjuvant in oral vaccine formulations. In the present work we further characterized its mechanism of action and studied the interaction and effect of U-Omp19 on the intestinal epithelium. We found that U-Omp19 inhibited protease activity from murine intestinal brush-border membranes and cysteine proteases from human intestinal epithelial cells (IECs) promoting co-administered Ag accumulation within lysosomal compartments of IECs. In addition, we have shown that co-administration of U-Omp19 facilitated the transcellular passage of Ag through epithelial cell monolayers in vitro and in vivo while did not affect epithelial cell barrier permeability. Finally, oral co-delivery of U-Omp19 in mice induced the production of Ag-specific IgA in feces and the increment of CD103+ CD11b- CD8α+ dendritic cells subset at Peyer's patches. Taken together, these data describe a new mechanism of action of a mucosal adjuvant and support the use of this rationale/strategy in new oral delivery systems for vaccines.
Subject(s)
Adjuvants, Immunologic/administration & dosage , Antigens, Bacterial/administration & dosage , Bacterial Outer Membrane Proteins/administration & dosage , Intestinal Mucosa/metabolism , Lipoproteins/administration & dosage , Protease Inhibitors/administration & dosage , Vaccines/administration & dosage , Administration, Oral , Animals , Caco-2 Cells , Epithelial Cells/metabolism , Female , HT29 Cells , Humans , Mice, Inbred BALB CABSTRACT
BACKGROUND: Prevention of Lyme disease in dogs in North America depends on effective vaccination against infection by the tick vector-born spirochete Borrelia burgdorferi. Most vaccines effectively prevent spirochete transmission to dogs during tick feeding based on immunization with the outer-surface lipoprotein A (OspA) of B. burgdorferi. More recently, vaccines containing additional OspC protein moieties have been introduced. These are designed to enhance protection by forming a second line of defense within the vertebrate host, where OspC expression replaces OspA as the dominant surface antigen. However, supportive data for demonstration of OspC mediated protection is still lacking. Since OspA immunogenicity is of paramount importance to protection against spirochete transmission; this study was designed to compare the immunogenicity of two commercially available vaccines against the Borrelia burgdorferi OspA. We further characterized OspA antigen fractions of these vaccines with respect to their biochemical and biophysical properties. RESULTS: Two groups of beagle dogs (n = 9) were administered either: (1) a nonadjuvanted/monovalent, recombinant OspA vaccine (Recombitek® Lyme) or (2) an adjuvanted, recombinant OspA /OspC chimeric fusion vaccine (Vanguard® crLyme). The onset of the anti-OspA antibody response elicited by the nonadjuvanted/monovalent OspA vaccine was significantly earlier than that for the bivalent OspA /OspC vaccine and serum borreliacidal activity was significantly greater at all post-vaccination time points. As expected, only dogs inoculated with the bivalent OspA/OspC vaccine mounted a humoral anti-OspC response. However, only three out of nine dogs in that group had a positive response. Comparison of the OspA vaccine structures revealed that the OspA in the nonadjuvanted/monovalent vaccine was primarily in the lipidated form, eluting (SEC-HPLC) at a high molecular weight, suggestive of micelle formation. Conversely, the OspA moiety of the OspA/OspC vaccine was found to be nonlipidated and eluted as the monomeric protein. CONCLUSIONS: We hypothesize that these structural differences may account for the superior immunogenicity of the nonadjuvanted monovalent recombinant OspA vaccine in dogs over the adjuvanted OspA fraction of the OspA/OspC vaccine.
Subject(s)
Antigens, Bacterial/immunology , Antigens, Surface/immunology , Bacterial Outer Membrane Proteins/immunology , Bacterial Vaccines/immunology , Borrelia burgdorferi/immunology , Dog Diseases/prevention & control , Lipoproteins/immunology , Lyme Disease/veterinary , Animals , Antibodies, Bacterial/blood , Antibody Formation , Antigens, Bacterial/administration & dosage , Antigens, Surface/administration & dosage , Bacterial Outer Membrane Proteins/administration & dosage , Bacterial Vaccines/administration & dosage , Dog Diseases/immunology , Dog Diseases/microbiology , Dogs , Female , Immunization , Lipoproteins/administration & dosage , Lyme Disease/immunology , Lyme Disease/prevention & control , Male , Vaccines, SyntheticABSTRACT
Heterogeneity in the metabolic properties of adipocytes in white adipose tissue has been well documented. We sought to investigate metabolic heterogeneity in adipocytes of brown adipose tissue (BAT), focusing on heterogeneity in nutrient uptake. To explore the possibility of metabolic heterogeneity in brown adipocytes, we used nanoscale secondary ion mass spectrometry (NanoSIMS) to quantify uptake of lipids in adipocytes interscapular BAT and perivascular adipose tissue (PVAT) after an intravenous injection of triglyceride-rich lipoproteins (TRLs) containing [2H]triglycerides (2H-TRLs). The uptake of deuterated lipids into brown adipocytes was quantified by NanoSIMS. We also examined 13C enrichment in brown adipocytes after administering [13C]glucose or 13C-labeled mixed fatty acids by gastric gavage. The uptake of 2H-TRLs-derived lipids into brown adipocytes was heterogeneous, with 2H enrichment in adjacent adipocytes varying by more than fourfold. We also observed substantial heterogeneity in 13C enrichment in adjacent brown adipocytes after administering [13C]glucose or [13C]fatty acids by gastric gavage. The uptake of nutrients by adjacent brown adipocytes within a single depot is variable, suggesting that there is heterogeneity in the metabolic properties of brown adipocytes.
Subject(s)
Adipocytes, Brown/metabolism , Nutrients/pharmacokinetics , Spectrometry, Mass, Secondary Ion/methods , Animals , Carbon Isotopes/analysis , Fatty Acids/pharmacokinetics , Glucose/pharmacokinetics , Lipids/pharmacokinetics , Lipoproteins/administration & dosage , Lipoproteins/pharmacokinetics , Mice, Inbred C57BL , Mice, Mutant Strains , Receptors, Lipoprotein/geneticsABSTRACT
PURPOSE: Nontypeable Haemophilus influenzae (NTHi) is a commensal in the human nasopharynx and the cause of pneumonia, meningitis, sinusitis, acute exacerbations of chronic obstructive pulmonary disease and acute otitis media (AOM). AOM is the most common ailment for which antibiotics are prescribed in the United States. With the emergence of new strains of antibiotic-resistant bacteria, finding an effective and broad coverage vaccine to protect against AOM-causing pathogens has become a priority. Mouse models are a cost-effective and efficient way to help determine vaccine efficacy. Here, we describe an NTHi AOM model in C57BL/6J mice, which also utilizes a mouse-adapted H1N1 influenza virus to mimic human coinfection. METHODOLOGY: We tested our coinfection model using a protein vaccine formulation containing protein D, a well-studied NTHi vaccine candidate that can be found in the 10-valent Streptococcus pneumoniae conjugate vaccine. We verified the usefulness of our mouse model by comparing bacterial loads in the nose and ear between protein D-vaccinated and control mice. RESULTS: While there was no measurable difference in nasal bacterial loads, we did detect significant differences in the bacterial loads of ear washes and ear bullae between vaccinated and control mice. CONCLUSION: The results from this study suggest that our NTHi AOM coinfection model is useful for assessing protein vaccines.
Subject(s)
Bacterial Proteins/immunology , Carrier Proteins/immunology , Haemophilus Infections/prevention & control , Haemophilus Vaccines/immunology , Haemophilus influenzae/immunology , Immunoglobulin D/immunology , Lipoproteins/immunology , Otitis Media/prevention & control , Administration, Intranasal , Animals , Antibodies, Bacterial/immunology , Bacterial Proteins/administration & dosage , Bacterial Proteins/genetics , Carrier Proteins/administration & dosage , Carrier Proteins/genetics , Coinfection/microbiology , Coinfection/prevention & control , Coinfection/virology , Disease Models, Animal , Female , Haemophilus Infections/microbiology , Haemophilus Vaccines/administration & dosage , Haemophilus Vaccines/genetics , Haemophilus influenzae/genetics , Haemophilus influenzae/growth & development , Humans , Immunoglobulin D/administration & dosage , Immunoglobulin D/genetics , Influenza A Virus, H1N1 Subtype/physiology , Lipoproteins/administration & dosage , Lipoproteins/genetics , Male , Mice , Mice, Inbred C57BL , Nose/microbiology , Nose/virology , Otitis Media/immunology , Otitis Media/microbiology , Vaccines, Conjugate/administration & dosage , Vaccines, Conjugate/immunologyABSTRACT
At early stages of Alzheimer's disease (AD), soluble amyloid beta (Aß) accumulates in brain while microglia are in resting state. Microglia can recognize Aß long after formation of plaques and release neurotoxic mediators. We examined impact of early minor activation of microglia by Toll-like receptors (TLRs) 2 and 4 agonists on Alzheimer's disease-related disturbed synaptic function and spatial memory in rats. Microglial BV-2 cells were treated by 0.1, 1, and 10 µg/mL of the TLRs ligands lipopolysaccharide, monophosphoryl lipid A (MPL), and Pam3Cys for 24 hours. Culture medium was then changed with media containing 1-µM Aß. Tumour necrosis factor (TNF)-α and CCL3 levels were measured in the supernatant, 24 hours thereafter. One µg of TLRs ligands which was able to release low level of TNF-α and CCL3, was administered intracerebroventricularly (i.c.v) to adult male rats every 3 days for 24 days. At the half of the treatment period, Aß1-42 was infused i.c.v (0.075 µg/hour) for 2 weeks. Finally, the following factors were measured: memory performance by Morris water maze, postsynaptic potentials of dentate gyrus following perforant pathway stimulation, hippocampal inflammatory cytokines interleukin 1 (IL-1)ß and TNF-α, anti-inflammatory cytokines IL-10 and TGF-1ß, microglia marker arginase 1, Aß deposits, and the receptor involved in Aß clearance, formyl peptide receptor 2 (FPR2). TLRs ligands caused dose-dependent release of TNF-α and CCL3 by BV-2 cells. Aß-treated cells did not release TNF-α and CCL3, whereas those pretreated with MPL and Pam3Cys significantly released these cytokines in response to Aß. Low-dose TLRs ligands improved the disturbance in spatial and working memory; restored the impaired long-term potentiation induced by Aß; decreased TNF-α, and Aß deposits; enhanced TGF-1ß, IL-10, and arginase 1 in the hippocampus of Aß-treated rats; and increased polarization of hippocampal microglia to the anti-inflammatory phenotype. The ligands increased formyl peptide receptor 2 in both BV-2 cells and hippocampus/cortex of Aß-treated rats. Microglia can sense/clear soluble Aß by early low-dose MPL and Pam3Cys and safeguard synaptic function and memory in rats.
Subject(s)
Alzheimer Disease/metabolism , Alzheimer Disease/psychology , Encephalitis/metabolism , Microglia/metabolism , Spatial Memory/physiology , Toll-Like Receptor 2/metabolism , Toll-Like Receptor 4/metabolism , Amyloid beta-Peptides/administration & dosage , Animals , Cell Line , Encephalitis/chemically induced , Hippocampus/drug effects , Hippocampus/physiology , Inflammation Mediators/metabolism , Lipid A/administration & dosage , Lipid A/analogs & derivatives , Lipoproteins/administration & dosage , Long-Term Potentiation , Mice , Rats, Wistar , Receptors, Lipoxin/metabolism , Toll-Like Receptors/agonistsABSTRACT
Berberine chloride (BER) is an antineoplastic phytomedicine that combat non-Hodgkin lymphoma. BER suffers from low oral bioavailability due to p-glycoprotein efflux and first-pass metabolism. Lymphatic drug targeting recently gained a profound attention due to circumventing hepatic first-pass metabolism and targeting lymph diseases. Therefore, novel BER-loaded cremochylomicrons were elaborated to mitigate BER drawbacks and enhance its lymphatic targeting and bioavailability. Optimized cremochylomicron was prepared with 2.5%w/v Cremophor El and 12.5% w/w berberine content. Promising in vitro characteristics (particle size = 175.6 nm and entrapment efficiency = 95.5%) were obtained. Lyophilized system showed high colloidal stability over 6 months. In addition in vivo pharmacokinetics study demonstrated significant enhancement (>2fold) in the rate and extent of absorption in cremochylomicron over free BER. Moreover, cremochylomicrons demonstrated in significant increase in mean residence time and volume of distribution with decreased intestinal drug clearance as a result of efflux inhibition. In another avenue, a significant reduction in BER absorption (43%) in presence of cycloheximide inhibitor was obtained confirming the lymphatic targeting ability of cremochylomicrons. In conclusion, berberine-loaded cremochylomicron could be considered as a promising nanoplatform for targeting lymphatic system and improving BER oral bioavailability with lower dose and side effects.